Digestive Diseases and Sciences

, Volume 64, Issue 11, pp 3115–3121 | Cite as

Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels

  • Walter Morales
  • Ali Rezaie
  • Gillian Barlow
  • Mark PimentelEmail author
Original Article



ELISA testing for anti-CdtB and anti-vinculin can discriminate patients with irritable bowel syndrome with diarrhea (IBS-D) from those with inflammatory bowel disease (IBD). However, recent findings suggest the antigens can suffer from epitope instability.


This study aimed to assess effects of incorporating epitope stabilization on test characteristics for distinguishing IBS-D from IBD subjects.


Plasma samples from IBS-D subjects from a large-scale clinical trial and subjects with endoscopically active IBD without concurrent immunomodulator therapy were used. After epitope stabilization, CdtB and vinculin were used in ELISA testing. Optical density readings were compared between IBS-D and IBD subjects.


Samples from 100 IBS-D and 31 IBD (22 UC and 9 CD) subjects were tested. IBS-D subjects had higher anti-CdtB titers (P = 0.0001) and higher anti-vinculin titers (P = 0.004) than IBD subjects. The specificities of anti-CdtB and anti-vinculin to differentiate IBS-D from IBD were 93.5% and 90.9%, respectively, with sensitivities of 43.0% and 52.2%, respectively. The positive likelihood ratios of identifying IBS-D with anti-CdtB and anti-vinculin were 6.7 and 5.7, respectively. Assuming a pretest probability of 57% for diagnosis of IBS-D in patients with abdominal pain and change in bowel habits, testing positive for both antibodies resulted in a posttest probability of > 98%.


Performing epitope stabilization for CdtB and vinculin enhances the test characteristics of ELISAs for anti-CdtB and anti-vinculin in discriminating IBS-D from IBD. Measurement of anti-CdtB and anti-vinculin with this second-generation methodology may further advance our understanding of the role of immunity in functional bowel diseases.


Epitope stabilization Cytolethal distending toxin Vinculin Enzyme-linked immunosorbent assay Diagnostic testing Irritable bowel syndrome 



We would like to acknowledge Gemelli Biotech Inc and Pacific Dx (Irvine, California) for performing the sample analyses.

Compliance with ethical standards

Conflict of interest

Cedars-Sinai has a licensing agreement with Salix Pharmaceuticals and Gemelli Biotech. Mark Pimentel is a founder of Gemelli Biotech, has equity in the company, and serves on the board. Ali Rezaie is a founder of Gemelli Biotech and also has equity in the company. Walter Morales is a consultant for Gemelli Biotech. Gillian Barlow has no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.


  1. 1.
    Choung RS, Locke GR 3rd. Epidemiology of IBS. Gastroenterol Clin North Am. 2011;40:1–10.PubMedGoogle Scholar
  2. 2.
    Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:e714.Google Scholar
  3. 3.
    Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150:1393–1407.Google Scholar
  4. 4.
    DA Drossman RJ, Talley NJ, et al. Functional gastrointestinal disorders: diagnosis, pathophysiology and treatment: a multinational consensus. Boston: Little, Brown; 1994.Google Scholar
  5. 5.
    Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45:II43–47.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.PubMedGoogle Scholar
  7. 7.
    American Gastroenterological Association. Guidelines–Rome III diagnostic criteria for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15:307–312.Google Scholar
  8. 8.
    Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503–3506.PubMedGoogle Scholar
  9. 9.
    Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412–419.PubMedGoogle Scholar
  10. 10.
    Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22:1157–1160.PubMedGoogle Scholar
  11. 11.
    Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol. 2006;52:89–95.PubMedGoogle Scholar
  12. 12.
    Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139–142.PubMedGoogle Scholar
  13. 13.
    Pimentel M. The prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome: IBS vs healthy controls (not historical definitions). Gut. 2008;57:1334–1335. (author reply 1335).PubMedGoogle Scholar
  14. 14.
    Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C, Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57:1321–1329.PubMedGoogle Scholar
  15. 15.
    Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut. 2002;51:410–413.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology. 2003;124:1662–1671.PubMedGoogle Scholar
  17. 17.
    Parry SD, Stansfield R, Jelley D, et al. Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A community-based, case-control study. Am J Gastroenterol. 2003;98:327–331.PubMedGoogle Scholar
  18. 18.
    Marshall JK, Thabane M, Garg AX, et al. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther. 2004;20:1317–1322.PubMedGoogle Scholar
  19. 19.
    Mearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology. 2005;129:98–104.PubMedGoogle Scholar
  20. 20.
    Klem F, Wadhwa A, Prokop LJ, et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology. 2017;152:e1041.Google Scholar
  21. 21.
    Pokkunuri V, Pimentel M, Morales W, et al. Role of cytolethal distending toxin in altered stool form and bowel phenotypes in a rat model of post-infectious irritable bowel syndrome. J Neurogastroenterol Motil. 2012;18:434–442.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Pimentel M, Morales W, Pokkunuri V, et al. Autoimmunity links vinculin to the pathophysiology of chronic functional bowel changes following Campylobacter jejuni infection in a rat model. Dig Dis Sci. 2015;60:1195–1205.PubMedGoogle Scholar
  23. 23.
    Parodi G, Morales W, Park SC, et al. Cytolethal distending toxin B (CdtB) exposure alone is sufficient to precipitate autoimmunity and changes to the small intestinal microbiome in a rat model of post-infectious IBS. Gastroenterology. 2017;152:S621.Google Scholar
  24. 24.
    Pimentel M, Morales W, Rezaie A, et al. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS ONE. 2015;10:e0126438.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Chira A, Dumitrascu DL. Serum biomarkers for irritable bowel syndrome. Clujul Med. 2015;88:258–264.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Schmulson M, Balbuena R, Corona de Law C. Clinical experience with the use of anti-CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico. Rev Gastroenterol Mex. 2016;81:236–239.PubMedGoogle Scholar
  27. 27.
    Pike BL, Paden KA, Alcala AN, et al. Immunological biomarkers in postinfectious irritable bowel syndrome. J Travel Med. 2015;22:242–250.PubMedGoogle Scholar
  28. 28.
    Rezaie A, Park SC, Morales W, et al. Assessment of anti-vinculin and anti-cytolethal distending toxin B antibodies in subtypes of irritable bowel syndrome. Dig Dis Sci. 2017;62:1480–1485.PubMedGoogle Scholar
  29. 29.
    Lombardero M, Heymann PW, Platts-Mills TA, Fox JW, Chapman MD. Conformational stability of B cell epitopes on group I and group II Dermatophagoides spp. allergens. Effect of thermal and chemical denaturation on the binding of murine IgG and human IgE antibodies. J Immunol. 1990;144:1353–1360.PubMedGoogle Scholar
  30. 30.
    Forsstrom B, Axnas BB, Rockberg J, Danielsson H, Bohlin A, Uhlen M. Dissecting antibodies with regards to linear and conformational epitopes. PLoS ONE. 2015;10:e0121673.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151:1113–1121.PubMedGoogle Scholar
  32. 32.
    Ford AC, Talley NJ, Veldhuyzen van Zanten SO, Vakil NB, Simel DL, Moayyedi P. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient’s lower gastrointestinal tract symptoms? JAMA. 2008;300:1793–1805.PubMedGoogle Scholar
  33. 33.
    American Gastroenterological Association. The burden of gastrointestinal diseases. Bethesda, MD: American Gastroenterological Association; 2001.Google Scholar
  34. 34.
    Sood R, Camilleri M, Gracie DJ, et al. Enhancing diagnostic performance of symptom-based criteria for irritable bowel syndrome by additional history and limited diagnostic evaluation. Am J Gastroenterol. 2016;111:1446–1454.PubMedGoogle Scholar
  35. 35.
    Shah ED, Riddle MS, Chang C, Pimentel M. Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome. J Neurogastroenterol Motil. 2012;18:200–204.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Pimentel M, Chatterjee S, Chang C, et al. A new rat model links two contemporary theories in irritable bowel syndrome. Dig Dis Sci. 2008;53:982–989.PubMedGoogle Scholar
  37. 37.
    Jee SR, Morales W, Low K, et al. ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. World J Gastroenterol. 2010;16:3680–3686.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Sung J, Morales W, Kim G, et al. Effect of repeated Campylobacter jejuni infection on gut flora and mucosal defense in a rat model of post infectious functional and microbial bowel changes. Neurogastroenterol Motil. 2013;25:529–537.PubMedGoogle Scholar
  39. 39.
    Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47:804–811.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Peng X, Cuff LE, Lawton CD, DeMali KA. Vinculin regulates cell-surface E-cadherin expression by binding to beta-catenin. J Cell Sci. 2010;123:567–577.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Peng X, Nelson ES, Maiers JL, DeMali KA. New insights into vinculin function and regulation. Int Rev Cell Mol Biol. 2011;287:191–231.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Demali KA. Vinculin—a dynamic regulator of cell adhesion. Trends Biochem Sci. 2004;29:565–567.PubMedGoogle Scholar
  43. 43.
    Shen K, Tolbert CE, Guilluy C, et al. The vinculin C-terminal hairpin mediates F-actin bundle formation, focal adhesion, and cell mechanical properties. J Biol Chem. 2011;286:45103–45115.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Xu W, Baribault H, Adamson ED. Vinculin knockout results in heart and brain defects during embryonic development. Development. 1998;125:327–337.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Medically Associated Science and Technology (MAST) ProgramCedars-Sinai Medical CenterLos AngelesUSA

Personalised recommendations